Previous 10 | Next 10 |
France's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal. Frontage Shanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO. Sinovac Biotech reported that a third dose of its inac...
Study findings demonstrate that a booster dose of inactivated COVID-19 vaccine produces a highly sifted, humoral immune response via a sustained evolution of antibodies, able to effectively neutralize SARS-CoV-2 variants of concern. SINOVAC Biotech Ltd. (NASDAQ: SVA) (ȁ...
SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (...
Doubling down his opposition to an early rollout of COVID-19 boosters, the Director-General of World Health Organization (WHO) urges rich countries with an excess supply of COVID-19 vaccines to halt their plans for booster shots through the end of the year. The head of the global agency Dr. T...
The World Health Organization (WHO) says that COVID-19 is likely “here to stay with us” as the virus mutates like flu viruses making its elimination unlikely. Speaking at a press briefing, Dr. Mike Ryan, the executive director of the WHO’s Health Emergencies Program said:...
BeyondSpring (BYSI -13.0%) has lost more than a tenth of its value to post its biggest intra-day drop since early August as the shares of clinical-stage biopharma company look set to extend the recent losses to the fourth consecutive session. However, BeyondSpring (NASDAQ:BYSI) has more than ...
The World Health Organization (WHO) says it is monitoring a new coronavirus variant named “mu,” which, according to the agency, has the potential to escape the immunity gained from COVID-19 vaccines or natural infection. On August 30, WHO has added the “mu” variant...
XtalPi, a US-China AI-based drug discovery company, completed a $400 million Series D financing at an estimated valuation of $2 billion. Shanghai's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers. Advaccine...
CoronaVac® generates good immune memory after second dose Third dose of vaccine significantly increased neutralizing antibody levels in adults and elderly population Findings indicate a third dose of CoronaVac® is well-tolerated in the elderly population ...
Inovio (NASDAQ:INO) perks up 2% premarket after receiving regulatory allowance for two clinical trials investigating heterologous boosting with INO-4800, its DNA vaccine candidate for COVID-19, through partner and trial-sponsor Advaccine Biopharmaceuticals Suzhou Co., Ltd. toge...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – May 1, 2024, Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) a clinical-stage biotechnology company focused on the development of regenerativ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual r...
--News Direct-- Dr. Philip Toleikis to retire as of April 30, 2024 Cost savings from restructuring and strategic transformation anticipated to extend runway Board rebuild underway LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - April 25, 2024 –...